Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 2 2Phase 1/2 2Phase 1 1

Status

Recruiting 4Active not recruiting 2Completed 1

Sponsor Class

OTHER 6NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

CNS 7Sarcoma 2

Conditions

Carcinoma, Non-Small-Cell Lung 55Carcinoma, Hepatocellular 53Lung Neoplasms 31Small Cell Lung Carcinoma 25Neoplasms 24Breast Neoplasms 20Colorectal Neoplasms 17Melanoma 15Triple Negative Breast Neoplasms 14Urinary Bladder Neoplasms 13Carcinoma, Transitional Cell 13Neoplasm Metastasis 12Carcinoma, Renal Cell 11Squamous Cell Carcinoma of Head and Neck 10Uterine Cervical Neoplasms 8Stomach Neoplasms 8Prostatic Neoplasms 7Glioblastoma 7Endometrial Neoplasms 7Ovarian Neoplasms 6Head and Neck Neoplasms 6Sarcoma 5Pancreatic Neoplasms 5Carcinoma, Neuroendocrine 5Carcinoma, Merkel Cell 5Liver Neoplasms 4Kidney Neoplasms 4Extensive Stage Lung Small Cell Carcinoma 4Carcinoma 4Brain Neoplasms 4

Interventions

Temozolomide 99Radiotherapy 51Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 23Bevacizumab 20Lomustine 16Nivolumab 14Surgical Procedures, Operative 11Cyclophosphamide 8Biopsy 8atezolizumab 7abemaciclib 7Ipilimumab 7fludarabine 6Radiotherapy, Intensity-Modulated 6Carboplatin 6olaparib 5Metformin 5Diet, Ketogenic 5Dianhydrogalactitol 5Aminolevulinic Acid 5regorafenib 4poly ICLC 4Radiosurgery 4Photons 4Leukapheresis 4Immunoglobulin G 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Glioblastoma × atezolizumab × 1 year × Clear all
NCT06069726 2026-04-21

MOAB

Duke University

Phase 2 Recruiting
80 enrolled
CNS

Glioblastoma

NCT07538128 2026-04-20

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Huashan Hospital

Phase EARLY_PHASE1 Recruiting
10 enrolled
CNS

Adenoviridae Infections, Glioblastoma

NCT04729959 2026-04-01

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
59 enrolled
CNS

Astrocytoma, Glioblastoma

NCT05423210 2025-12-22

Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme

Stony Brook University

Phase EARLY_PHASE1 Recruiting
12 enrolled
CNS

Glioblastoma

NCT05039281 2025-12-19

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
6 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03174197 2025-09-24

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

M.D. Anderson Cancer Center

Phase 1/2 Completed
60 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04808245 2025-09-22

INTERCEPT-H3

German Cancer Research Center

Phase 1 Active not recruiting
15 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡